Atlas Trials

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Clinical trial NCT07460206 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07460206
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
ccRCC
Start date
2026-08-01
Primary completion
2031-08-01
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.